-
Mashup Score: 14Systemic Therapy Options for Peritoneal Mesothelioma - 5 month(s) ago
Peritoneal mesothelioma is an uncommon malignancy affecting approximately 300 new patients annually in the United States. Due to its low incidence, prospective clinical trials specific to this disease are scant. Recommendations regarding systemic therapy are mostly extrapolated from clinical trials conducted among patients with pleural mesothelioma. At present, the recommended first-line systemic treatment options may include immunotherapy with nivolumab plus ipilimumab or chemotherapy with pemetrexed plus either cisplatin or carboplatin. For second-line treatment, the other previously unchosen first-line option can be used. Off-label bevacizumab may be considered in combination with chemotherapy among carefully selected patients. The benefit of third-line treatment or beyond is less clear. Nonetheless, a number of single-agent regimens show modest activity. Anecdotal reports of children or young adults with peritoneal mesothelioma harboring ALK rearrangement have suggested the efficac
Source: jnccn.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related Financial Toxicity - 5 month(s) ago
Background: Although the need to reduce the impact of financial toxicity among patients with cancer is widely acknowledged, few interventions have been developed to address this issue. We tested a novel, multiphase, patient-centered financial navigation (FN) intervention at a large academic medical center. Methods: We developed a financial toxicity screening tool consisting of the Comprehensive Score for Financial Toxicity (COST) measure plus several additional items based on patient feedback. After systematizing the screening process, 50 patients from the North Carolina Basnight Cancer Hospital were enrolled in the FN intervention following a positive screen for financial distress (COST score <23). The FN intervention involved one-on-one consultations with a trained financial navigator and included an initial comprehensive intake appointment to determine patient eligibility for financial assistance and follow-up appointments to discuss paperwork and application(s) status. We assessed
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related #FinancialToxicity: https://t.co/VsCdvkErvA https://t.co/7jidY44EH9
-
-
Mashup Score: 0Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests - 5 month(s) ago
Background: Some genomic alterations in non–small cell lung cancer (NSCLC) are known to differ according to race, sex, or age. These studies have been limited in sample size and thus they cannot detect the differences precisely and comprehensively. Methods: Tissue-based comprehensive genomic profiling was performed on 75,362 patients with NSCLC from the United States during routine clinical care. Additionally, we examined data of a Japanese NSCLC cohort with 1,019 patients. In the US cohort, 296 genes were examined for pathogenic alterations. Predominant genetic ancestry was inferred using a SNP-based approach, and patients were categorized into European (EUR), African (AFR), East Asian (EAS), Admixed American (AMR), and South Asian (SAS) ancestry groups. Patients were additionally stratified by histologic type, age (<40/≥40 years, <75/≥75 years), and sex. The prevalence of high tumor mutational burden (TMB-High) and microsatellite instability status was also calculated. Results: Strat
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in #NSCLC: From the Real-World Data of Cancer #GenomicProfiling Tests: https://t.co/XfvcNSn7JY #LCSM #cagenome https://t.co/de3vsgrJz9
-
-
Mashup Score: 0Tailoring Escalation Adjuvant Therapy for Early-Stage Triple-Negative Breast Cancer in the CBCSG010 Clinical Trial Biomarker Analysis - 5 month(s) ago
Background: Triple-negative breast cancer (TNBC) is a highly heterogeneous disease. The CBCSG010 trial is a prospective and multicenter phase III clinical trial confirming that adding adjuvant capecitabine significantly improved the 5-year disease-free survival (DFS) rate in patients with TNBC by 5.9%. In this study, we attempted to identify the specific population that benefited from adjuvant therapy. Methods: In this retrospective exploratory analysis, we performed RNA sequencing of tumor tissues from patients with TNBC in the CBCSG010 clinical trial. A single-sample gene set enrichment analysis algorithm and survival analysis were performed to characterize the intrinsic molecular features of the TNBC microenvironment and assess the associations between immune-related gene expression levels or immune cell counts with capecitabine treatment efficacy. Additionally, we performed immunohistochemical staining of 2 markers, PD-L1 and CD8, and hematoxylin-eosin staining of stromal tumor–inf
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Tailoring Escalation Adjuvant Therapy for Early-Stage Triple-Negative #BreastCancer in the CBCSG010 Clinical Trial Biomarker Analysis: https://t.co/8Z9dWTMe6a #BCSM #TNBC https://t.co/2WT6h5bsl9
-
-
Mashup Score: 34Is it Time to Forget the 5-Fluorouracil Bolus? - 5 month(s) ago
“Is it Time to Forget the 5-Fluorouracil Bolus?” published on Oct 2024 by National Comprehensive Cancer Network.
Source: jnccn.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @dr_yakupergun: Is it Time to Forget the 5-Fluorouracil Bolus? @JNCCN https://t.co/ZJ60TzcqWF https://t.co/8Avon2kdON
-
-
Mashup Score: 34Is it Time to Forget the 5-Fluorouracil Bolus? - 5 month(s) ago
“Is it Time to Forget the 5-Fluorouracil Bolus?” published on Oct 2024 by National Comprehensive Cancer Network.
Source: jnccn.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @dr_yakupergun: Is it Time to Forget the 5-Fluorouracil Bolus? @JNCCN https://t.co/ZJ60TzcqWF https://t.co/8Avon2kdON
-
-
Mashup Score: 13Rehabilitation in Oncology Care Guidelines: A Gap Analysis - 5 month(s) ago
Background: Cancer survivors experience a high prevalence of functional impairments. Rehabilitation interventions include an expansive array of services that can help optimize function, address pain, decrease symptom burden, and improve quality of life. Nonetheless, rehabilitation services remain underutilized. Thus, it is important to enhance the understanding of and establish guidelines for specific rehabilitation disciplines and interventions. Methods: This is a gap analysis of rehabilitation recommendations in published oncology guidelines from selected nationally recognized organizations. Symptom-specific guidelines and cancer type–specific guidelines were analyzed for inclusion of common functional impairments (fatigue, pain, peripheral neuropathy, cognitive dysfunction, and lymphedema) and the rehabilitation discipline recommendations. Results: The prevalence of recommendations for rehabilitation in cancer type–specific guidelines was 29%, and was higher in symptom-specific guid
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Rehabilitation in #Oncology Care Guidelines: A Gap Analysis: https://t.co/mUjZCjT7hV #supponc https://t.co/Gl03SqyJwL
-
-
Mashup Score: 13Rehabilitation in Oncology Care Guidelines: A Gap Analysis - 5 month(s) ago
Background: Cancer survivors experience a high prevalence of functional impairments. Rehabilitation interventions include an expansive array of services that can help optimize function, address pain, decrease symptom burden, and improve quality of life. Nonetheless, rehabilitation services remain underutilized. Thus, it is important to enhance the understanding of and establish guidelines for specific rehabilitation disciplines and interventions. Methods: This is a gap analysis of rehabilitation recommendations in published oncology guidelines from selected nationally recognized organizations. Symptom-specific guidelines and cancer type–specific guidelines were analyzed for inclusion of common functional impairments (fatigue, pain, peripheral neuropathy, cognitive dysfunction, and lymphedema) and the rehabilitation discipline recommendations. Results: The prevalence of recommendations for rehabilitation in cancer type–specific guidelines was 29%, and was higher in symptom-specific guid
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Rehabilitation in #Oncology Care Guidelines: A Gap Analysis: https://t.co/mUjZCjT7hV #supponc https://t.co/Gl03SqyJwL
-
-
Mashup Score: 33Is it Time to Forget the 5-Fluorouracil Bolus? - 5 month(s) ago
“Is it Time to Forget the 5-Fluorouracil Bolus?” published on Oct 2024 by National Comprehensive Cancer Network.
Source: jnccn.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @dr_yakupergun: Is it Time to Forget the 5-Fluorouracil Bolus? @JNCCN https://t.co/ZJ60TzcqWF https://t.co/8Avon2kdON
-
-
Mashup Score: 5JNCCN - 6 month(s) ago
JNCCN
Source: jnccn.orgCategories: General Medicine News, Onc News and JournalsTweet-
The August issue of @JNCCN is now available online! Featured: @NCCN Guidelines on Adolescent and Young Adult (#AYA) Oncology, insights into recent updates to #NCCNGuidelines for #Survivorship, and more! https://t.co/8t8aPaSww2 #AYAcsm #survonc https://t.co/WiN2kzpsqA
-
RT @Erman_Akkus: 📘Systemic Therapy Options for Peritoneal Mesothelioma @JNCCN 👉https://t.co/sKh1sBB7ij @NCCN @OncoAlert #cancer #Oncolog…